DE69835612D1 - Methoden zur regulierung der serin/threonin protein kinase funktion mit 5-azaquinoxalinderivaten - Google Patents

Methoden zur regulierung der serin/threonin protein kinase funktion mit 5-azaquinoxalinderivaten

Info

Publication number
DE69835612D1
DE69835612D1 DE69835612T DE69835612T DE69835612D1 DE 69835612 D1 DE69835612 D1 DE 69835612D1 DE 69835612 T DE69835612 T DE 69835612T DE 69835612 T DE69835612 T DE 69835612T DE 69835612 D1 DE69835612 D1 DE 69835612D1
Authority
DE
Germany
Prior art keywords
azaquinoxaline
serin
regulating
derivatives
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69835612T
Other languages
English (en)
Other versions
DE69835612T2 (de
Inventor
Gerald Mcmahon
Bernhard Kutscher
Eckhard Gunther
Harald App
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of DE69835612D1 publication Critical patent/DE69835612D1/de
Application granted granted Critical
Publication of DE69835612T2 publication Critical patent/DE69835612T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69835612T 1997-10-06 1998-10-05 Methoden zur regulierung der serin/threonin protein kinase funktion mit 5-azaquinoxalinderivaten Expired - Fee Related DE69835612T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06
US61123P 1997-10-06
PCT/US1998/020910 WO1999017759A2 (en) 1997-10-06 1998-10-05 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds

Publications (2)

Publication Number Publication Date
DE69835612D1 true DE69835612D1 (de) 2006-09-28
DE69835612T2 DE69835612T2 (de) 2007-08-16

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835612T Expired - Fee Related DE69835612T2 (de) 1997-10-06 1998-10-05 Methoden zur regulierung der serin/threonin protein kinase funktion mit 5-azaquinoxalinderivaten

Country Status (31)

Country Link
US (2) US6180631B1 (de)
EP (1) EP1028729B1 (de)
JP (1) JP2001518496A (de)
KR (1) KR100633270B1 (de)
CN (1) CN1169527C (de)
AR (1) AR013542A1 (de)
AT (1) ATE336250T1 (de)
AU (1) AU757585B2 (de)
BG (1) BG64969B1 (de)
BR (1) BR9814814A (de)
CA (1) CA2306257C (de)
CY (1) CY1106223T1 (de)
CZ (1) CZ298775B6 (de)
DE (1) DE69835612T2 (de)
DK (1) DK1028729T3 (de)
ES (1) ES2268791T3 (de)
HK (1) HK1031836A1 (de)
HU (1) HUP0100302A3 (de)
IL (2) IL135103A0 (de)
MX (1) MXPA03011007A (de)
NO (1) NO316598B1 (de)
NZ (1) NZ503431A (de)
PL (1) PL192039B1 (de)
PT (1) PT1028729E (de)
RU (1) RU2223753C2 (de)
SK (1) SK4722000A3 (de)
TR (2) TR200000906T2 (de)
TW (1) TWI245765B (de)
UA (1) UA71555C2 (de)
WO (1) WO1999017759A2 (de)
ZA (1) ZA988961B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
AU2003209116A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2004027361A1 (en) * 2002-09-17 2004-04-01 University Of Virginia Patent Foundation Remote temperature sensing of small volume and related apparatus thereof
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
EP1636228B1 (de) * 2003-05-23 2008-10-22 AEterna Zentaris GmbH Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
US20060293340A1 (en) * 2003-06-13 2006-12-28 Novartis Ag 2-Aminopyrimidine derivatives as raf kinase inhibitors
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
CA2628039A1 (en) * 2005-11-11 2007-05-18 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (de) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazinderivate und ihre Verwendungen
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014109414A1 (ja) * 2013-01-11 2014-07-17 富士フイルム株式会社 含窒素複素環化合物またはその塩
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
EP3848034A1 (de) 2014-03-26 2021-07-14 Astex Therapeutics Limited Kombinationen
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
US12012394B2 (en) * 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
EP0586608A1 (de) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclische polyhydroxy tyrosin-kinase-inhibitoren
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2140440A1 (en) 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Also Published As

Publication number Publication date
HUP0100302A2 (hu) 2001-06-28
CA2306257A1 (en) 1999-04-15
US6180631B1 (en) 2001-01-30
DK1028729T3 (da) 2006-12-11
DE69835612T2 (de) 2007-08-16
CN1274284A (zh) 2000-11-22
BG104392A (en) 2000-12-29
PL339860A1 (en) 2001-01-15
EP1028729B1 (de) 2006-08-16
ES2268791T3 (es) 2007-03-16
BG64969B1 (bg) 2006-11-30
AR013542A1 (es) 2000-12-27
NO20001748L (no) 2000-04-05
HUP0100302A3 (en) 2006-03-28
CY1106223T1 (el) 2011-06-08
IL135103A0 (en) 2001-05-20
SK4722000A3 (en) 2002-06-04
AU757585B2 (en) 2003-02-27
MXPA03011007A (es) 2004-02-27
UA71555C2 (en) 2004-12-15
BR9814814A (pt) 2000-10-03
WO1999017759A3 (en) 2000-01-06
EP1028729A2 (de) 2000-08-23
JP2001518496A (ja) 2001-10-16
CZ20001129A3 (cs) 2000-10-11
AU9514198A (en) 1999-04-27
NO20001748D0 (no) 2000-04-05
NO316598B1 (no) 2004-03-01
US6727252B1 (en) 2004-04-27
ZA988961B (en) 1999-10-04
PL192039B1 (pl) 2006-08-31
CA2306257C (en) 2007-09-25
TWI245765B (en) 2005-12-21
ATE336250T1 (de) 2006-09-15
TR200100385T2 (tr) 2002-06-21
KR20010030934A (ko) 2001-04-16
CZ298775B6 (cs) 2008-01-23
PT1028729E (pt) 2006-12-29
RU2223753C2 (ru) 2004-02-20
KR100633270B1 (ko) 2006-10-16
NZ503431A (en) 2002-07-26
HK1031836A1 (en) 2001-06-29
WO1999017759A2 (en) 1999-04-15
CN1169527C (zh) 2004-10-06
TR200000906T2 (tr) 2000-11-21
IL135103A (en) 2007-06-17

Similar Documents

Publication Publication Date Title
DE69835612D1 (de) Methoden zur regulierung der serin/threonin protein kinase funktion mit 5-azaquinoxalinderivaten
NO20001555L (no) Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon
DE69700302T2 (de) Obturator zum kalibrieren von künstlichen aortenklappen
DE69732992D1 (de) Stent mit variablen Eigenschaften zur Stützoptimierung
NO20001242L (no) April - et nytt protein med veksteffekter
DE69105994D1 (de) Monatsbinde mit zur separaten verwendung geeigneten komponenten.
DE69713295D1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
DE69714966T2 (de) Antikörper gegen cd 18 zur verwendung gegen gehirnschlag
DE69711537T2 (de) Zementierstopfen für Bohrloch
DE19781795T1 (de) Kraftstoffzuführungs-Meßsystem mit automatischer Pumpenanpassung
DE69506387T2 (de) Bindungstest unter verwendung von agenzien mit schwanzgruppen
DE69938163D1 (de) Programmiertes Funkgerät zur automatischen Erfassung von Verzeichnisdaten
DE69612888D1 (de) Techniken zur Regelung von entfernten Lampenlasten
DE69526476D1 (de) Vorrichtung mit Flash-Speichersteuerung zur Änderung
DE69412752T2 (de) Kopierverfahren zur Feststellung der Grösse einer Beleuchtungsfarbkorrektur mittels abgeleiteter Beleuchtungsdatenerfassung
DE69817470D1 (de) Kathodische Elektrotauchlackierung mit Carbamat-funktionellen Vernetzungsmitteln
DE69612006T2 (de) Methode zur gefässerweiterung mit (1,5-inter)arylprostaglandinderivaten
DE3878375D1 (de) Proportionalventil zur verwendung bei blockierverhinderern.
DE69700968T2 (de) Drucker mit Verfahren zur Steuerung derselben
DE69804770T2 (de) Verfahren zur herstellung von halogenkohlenwasserstoffen
ATE243857T1 (de) System zur zufuhr von toner
DE19981770D2 (de) Verfahren zur Bereitstellung von künstlichen Rezeptoren
NO982323D0 (no) FremgangsmÕte til regulering av algevekst
DE60027112D1 (de) Steuerungsverfahren für ein Automatgetriebe mit Berücksichtigung der Fahrbahnneigung
DE69815839D1 (de) Ladungsgesteuerte schaltung zur rasterkorrektur

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AETERNA ZENTARIS GMBH, 60314 FRANKFURT, DE

8339 Ceased/non-payment of the annual fee